A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Crenezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms CREAD OLE
- Sponsors Roche
- 29 Jul 2019 Status changed from active, no longer recruiting to completed.
- 19 Jun 2019 This trial has been completed in Hungary.
- 07 Jun 2019 This trial has been completed in Belgium.